文献速递乳房整形与再造

酮咯酸与乳房切除术后植入物乳房再造血肿发生率

Ketorolac and Hematoma Incidence in Postmastectomy Implant-Based Breast Reconstruction.
PubMed 文献 · Ann Plast Surg · 2018-01-01

单中心回顾性分析2008至2013年前瞻性数据库522例患者中180例假体乳房再造者,其中57例术中使用酮咯酸。对照组临床相关血肿发生率为0.09(11/123,95%CI 0.05-0.15),酮咯酸组为0.04(2/57,95%CI 0.01-0.12),P=0.32,无统计学显著差异;总并发症数与住院时长亦无显著差异。

要点

  • 术中使用酮咯酸组临床相关血肿发生率为0.04(2/57),对照组为0.09(11/123),P=0.32
  • 两组总并发症数量与住院时长无统计学显著差异
  • 该研究为单中心回顾性分析,作者未发现酮咯酸与血肿发生率升高相关的趋势

核心结论

  • 回顾乳房再造数据库未发现植入物乳房切除术后再造术中使用酮咯酸与血肿发生率升高相关的趋势。

研究设计与样本

  • 单中心回顾性分析,分析本机构在乳房切除术后非自体植入物乳房再造中使用酮咯酸的经验。
  • 分析2008年至2013年收集的522例患者前瞻性数据库,其中180例接受假体再造,57例术中使用酮咯酸。

主要发现

  • 对照组临床相关血肿发生率为0.09(11/123例,95%CI 0.05-0.15),酮咯酸组为0.04(2/57例,95%CI 0.01-0.12),P=0.32。
  • 酮咯酸组与对照组在总并发症数量上未检测到统计学显著差异。
  • 酮咯酸组与对照组在住院时长上未检测到统计学显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ketorolac tromethamine (Toradol) is an effective a nonsteroidal anti-inflammatory drug and a powerful analgesic for patients undergoing breast surgery. However, the potential for postoperative bleeding has not yet been explored specifically in women undergoing implant-based breast reconstruction. There is concern that an increased risk of bleeding exists in this population due to the lack of tissue apposition as a result of implant placement. We therefore seek to assess the associated risk of bleeding complication in implant-based breast reconstruction at our academic institution. To the best of our knowledge, this represents the first case series addressing safety profile of Toradol specifically in patients undergoing nonautologous, implant-based breast reconstruction. METHODS/RESULTS: A single-center, retrospective review was performed analyzing our institutional experience with Toradol in nonautologous, implant-based breast reconstruction following mastectomy. A prospective database of 522 patients collected between 2008 and 2013 was analyzed. Within the database, 57 patients who received intraoperative ketorolac were identified among a total of 180 patients undergoing prosthetic reconstruction. No statistically significant difference was found in the incidence of clinically relevant hematoma formation between the control and Toradol groups. The frequency of hematoma formation in the control was 0.09 (11/123 patients, 95% confidence interval = 0.05-0.15) and 0.04 in the Toradol group (2/57 patients, 95% confidence interval = 0.01-0.12), resulting in a P value of 0.32. Regarding the secondary outcomes, we did not detect a statistically significant difference in the total number of complications or length of hospital stay in the Toradol and control groups. CONCLUSIONS: Review of our breast reconstruction database did not find a trend toward an elevated incidence of hematoma associated with intraoperative Toradol use in implant-based postmastectomy reconstruction.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Mikhaylov Y, Weinstein B, Schrank TP, et al. Ketorolac and Hematoma Incidence in Postmastectomy Implant-Based Breast Reconstruction. Ann Plast Surg. 2018. PMID: 29538000. doi:10.1097/SAP.0000000000001409

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。